Edgewise Therapeutics, Inc. (EWTX)

Market Cap	542.37M
Revenue (ttm)	n/a
Net Income (ttm)	-60.92M
Shares Out	51.84M
EPS (ttm)	2.89
PE Ratio	3.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	205,267
Open	8.51
Previous Close	8.58
Day's Range	8.3 - 8.91
52-Week Range	5.41 - 22.41
Beta	n/a
Analysts	Buy
Price Target	24.28 (+174.0%)
Earnings Date	Nov 9, 2022

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise T...

• Industry: Biotechnology
• IPO Date: Mar 26, 2021
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: EWTX

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is 24.28, which is an increase of 174.04% from the latest price.

Price Target

$24.28

(174.04% upside)

Analyst Consensus: Buy

Stock Forecasts